



**Contact:**

David Waldman or Justyna Gudaszewska  
Crescendo Communications Europe Sp. z o.o.  
Email: [mmd@crescendo-ir.com](mailto:mmd@crescendo-ir.com)  
Tel: + 48 71 79 11 551

**Milestone Medical Inc. to Present at SeeThruEquity First Annual Warsaw Investor Conference**

**LIVINGSTON, NJ, April 7, 2015 – Milestone Medical Inc. (WARSAW: MMD)**, today announced that Leonard Osser, Chief Executive Officer, will present at the upcoming SeeThruEquity First Annual Warsaw Investor Conference on Friday, June 12, 2015 in Warsaw, Poland. The event brings together executives from presenting companies with hundreds of leading institutional investors, industry professionals, fund managers and analysts looking for new ideas, investment opportunities and corporate relationships. The conference will be a one-day event with numerous networking opportunities available throughout the day. Investors will have access to Milestone Medical's management through a corporate presentation and individual meetings.

Members of the investment community interested in meeting the Company's management during the conference should register at the following website: [www.seethruequity.com](http://www.seethruequity.com).

Leonard Osser, CEO of Milestone Medical commented, "We look forward to meeting and speaking with interested investors about our future prospects, opportunities and the progress in commercial launch of our epidural and intra-articular drug delivery instruments in both Europe and the U.S. We believe that our participation in the conference will help us more proactively communicate our business model to the investment community."

**About Milestone Medical Inc.**

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval in the U.S. and has recently received CE approval for both instruments in the European Union. For more information please visit [www.medicalmilestone.com](http://www.medicalmilestone.com).

**About SeeThruEquity**

SeeThruEquity is an equity research and corporate access firm focused on companies with less than \$1 billion in market capitalization. The Company's research is not paid for and unbiased as it does not conduct any investment banking or commission based business. SeeThruEquity's research is contributed to by Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distributed to its opt-in investors along with Thomson Estimates, the leading estimates platform on Wall Street.

SeeThruEquity Conferences are held approximately every quarter throughout the year and host industry professionals and investors. Since the inception of the firm in 2011, SeeThruEquity has successfully organized 14 investor conferences, has collectively showcased over 200 of the companies in the market across a variety of sectors, has drawn over 3000

investors and industry professionals and has arranged over 1000 individual meetings for presenting companies. For more information, visit [www.seethruequity.com](http://www.seethruequity.com).

**Safe Harbor Statement**

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*